Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-24 12:04 |
6-K
|
English | 36.0 KB | ||
| 2025-01-22 07:00 |
Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en…
|
French | 186.0 KB | ||
| 2025-01-22 07:00 |
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in co…
|
English | 175.5 KB | ||
| 2025-01-21 07:00 |
Communiqué de presse : Opella : étape clé franchie pour l’étude consacrée au Ci…
|
French | 154.6 KB | ||
| 2025-01-21 07:00 |
Press Release: Opella reaches study milestone for Cialis
|
English | 151.9 KB | ||
| 2025-01-15 18:30 |
Sanofi: Information concerning the total number of voting rights and shares – N…
|
English | 145.3 KB | ||
| 2025-01-15 18:30 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novem…
|
French | 121.4 KB | ||
| 2025-01-14 14:40 |
6-K
|
English | 39.2 KB | ||
| 2025-01-13 07:00 |
Communiqué de presse : Sarclisa : première approbation en Chine pour le traitem…
|
French | 191.2 KB | ||
| 2025-01-13 07:00 |
Press Release: Sarclisa obtains first approval in China for the treatment of ad…
|
English | 187.9 KB | ||
| 2025-01-09 07:00 |
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints i…
|
English | 214.1 KB | ||
| 2025-01-09 07:00 |
Communiqué de presse : La nouvelle formulation sous-cutanée du Sarclisa a satis…
|
French | 228.1 KB | ||
| 2024-12-23 20:08 |
6-K
|
English | 26.4 KB | ||
| 2024-12-23 07:00 |
Communiqué de presse : Sanofi lance un programme de phase III pour son vaccin V…
|
French | 176.2 KB | ||
| 2024-12-23 07:00 |
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collabora…
|
English | 183.1 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
